Intercept Pharmaceticals & Chelsea Therapeutics: Which is Best?

Intercept Pharmaceuticals and Chelsea Therapeutics both rallied with remarkable gains, but do both stocks still have further upside, or can we expect volatile Sarepta Therapeutics-like years ahead?

Jan 23, 2014 at 10:30AM

In a five day period, two stocks, Intercept Pharmaceuticals (NASDAQ:ICPT) and Chelsea Therapeutics (NASDAQ:CHTP), exploded with gains following drug-related catalysts. And while both companies have appreciated greatly, are either a good buy? Or, are the rallies premature, much like Sarepta Therapeutics (NASDAQ:SRPT) in recent memory?

What moved Intercept?
Intercept rallied an unheard of 516% recently in regards to its Phase 2 drug obeticholic acid (OCA). The product was being tested to treat a disease called nonalcoholic steatohepatitis (NASH), and was stopped early after interim data revealed that its primary endpoint had been met .

With OCA showing an unquestioned benefit over placebo, Intercept stands ready to have the first FDA approved drug to treat a disease that effects more than six million people in the U.S. According to Bank of America, OCA could earn peak sales of $4 billion by treating this one disease. Therefore, from a valuation perspective, Intercept is now trading at 1.35 times peak sales, having a market cap of $5.5 billion.

What moved Chelsea?
Chelsea doubled in stock price after the company received an overwhelming vote of confidence (16:1) from an advisory panel for its drug Northera . The drug treats a rare form of blood pressure, but its fate had been one of the hot topics in biotechnology over the last few months.

Back in 2012 the FDA rejected Northera after receiving a positive recommendation from the advisory board. However, with a 16:1 vote in favor of approval, investors have to believe that Chelsea has a good shot at finally earning an approval. If so, Chelsea estimates that peak revenue of Northera could range between $300 and $375 million annually for this single indication . While Northera won't earn blockbuster sales on this FDA approval, Chelsea is not a company priced for billion dollar sales, trading with a market cap of $345 million. Thus, Chelsea trades at about one times peak sales.

Other investment factors

If we are looking at peak sales relative to market capitalization as the only indicator, then clearly Chelsea is presenting more value. Moreover, Chelsea has already received a positive advisory vote and is apparently weeks from an FDA approved product. For Intercept, we assume that it won't have to complete a Phase 3 study, but investors should be cautious --- many made a similar assumption with Sarepta Therapeutics last year.

Sarepta soared from $15 to $40 in a single session in 2012, after a Phase 2 trial showed incredible results in treating a rare degenerative genetic disease. Many thought this Phase 2 study alone would be enough to justify an early FDA approval, but late last year shares fell abruptly after the FDA begged to differ. While Intercept's Phase 2 trial is larger than Sarepta's, the same risk applies.

As noted, Chelsea will make it to market first, most likely, and also has less potential competitors. For Intercept, it could very likely compete with Gilead Sciences and Isis Pharmaceuticals, both of which are developing drugs to treat NASH.

Therefore, it appears as though Chelsea is the clear-cut-winner, but before we celebrate there is one final element to the story, and that of course is the pipeline of these two companies.

What do the pipelines look like?

Neither Chelsea nor Intercept have a pipeline full of drugs. However, both companies have several ongoing studies testing the two products that led to such large gains.

Intercept has a robust pipeline testing OCA in several similar diseases to NASH. In fact, most who follow the company considered its Phase 3 trial in treating primary biliary cirrhosis (PBC) the most near-term catalyst, meaning the NASH results really did come from nowhere. With that said, given OCA's success in treating NASH, investors might now be particularly excited about its likelihood to successfully treat PBC or any of the other three Phase 2 indications . Clearly, if all are successful, OCA could earn more than $4 billion in peak sales.

Chelsea hasn't developed Northera quite as deep, but does have two Phase 2 trials for Intradialytic Hypotension and Fibromyalgia. Combined, if successful, these two indications could add another $700 million in annual sales , thus making Northera a blockbuster. However, given the controversies that surrounded Northera and its 2012 FDA rejection, it might not be wise to make any conclusions or assumptions about these two indications just yet.

Final Thoughts
Both of these companies look to have a lot of promise, Intercept clearly with more revenue potential but also priced significantly higher. Thus, for investors comfortable with risk and searching for high upside potential, Chelsea might have the best ratio.

Keep in mind that the company still has to gain FDA approval for Northera. However, Intercept is still years from getting OCA in the market, as it won't read-out its final data until the year end. Then, like Sarepta, investors will live with the fear of what the FDA might decide as it relates to a possible Phase 3 study. Hopefully, Intercept won't have to complete a Phase 3 study, but at this point there is no way to know with absolute certainty. And if so, will it still be the first NASH treatment to market, because if not, peak estimated sales are unlikely to be met.

With that said, Chelsea had a great outcome with the advisory panel, and if approved, won't have any near-term competition.  Not to mention, Northera has rather low expectations; expectations for OCA are sky high, and by the time it's FDA approved, who knows what the competitive landscape will look like.

While Intercept's pipeline has more promise, as of today, and in the immediate future, both stock gains and valuations are tied to these two drugs and the one indication that created such large gains. Hence, Chelsea looks cheaper considering its peak sales outlook for this one indication, and assuming it's FDA approved, will be on the market creating revenue sooner than OCA. Therefore, Cheslea looks to be presenting the best risk-to-reward ratio right now, but keep an eye on pipeline development, future data, and meetings with the FDA, because Intercept's long-term future could be very bright as well.

Biotech stocks to watch today
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Brian Nichols has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers